– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology April 20, 2026 --- Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in patients with hepatocellular carcinoma

Data demonstrate potent multi-target activity, high specificity, and a novel approach to overcoming fundamental limitations of T cell engagers in solid tumors April 20, 2026 -- Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17–22 in San Diego, California. The data were included

AstraZeneca announced Tuesday that a Phase III study of Ultomiris (ravulizumab) in adults with IgA nephropathy (IgAN) met its primary endpoint, setting up marketing applications for the long-acting C5 complement inhibitor in this indication. "These positive data demonstrate that C5 complement inhibition with Ultomiris results in a rapid and clinically meaningful reduction in proteinuria as early as week 10 and underscores its potential as a disease-modifying approach in IgAN," said Marc Dunoyer

ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual Meeting ADCE-D01, a first-in-class uPARAP targeted ADC, granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) First patient dosed in Phase I trial of ADCE-B05, an ADC directed against an undisclosed first-in-cla

April 21, 2026 -- Ionetix Corporation ("Ionetix"), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space announced today it raised more than $30 million in a private placement offering at $3.00 per share. In addition, the company completed a go-public reverse merger transaction with JDEV Acquisition Corp., which has been renamed Ionetix Corp. Ionetix's patent-protected superconducting cyclotron technology supports unique particle accelerator s

Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion's commitment to elevating the standard of care and addressing unmet medical need in gastroenterology April 21, 2026 -- Celltrion, Inc. today announced that seven abstrac

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care April 20, 2026 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer

April 20, 2026 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global market Agreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biog

April 20, 2026 -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies. Autologous CAR-T therapy has achieved remarkable success in hematologic malignancies, yet its widespread use remains challenging